


## **Reporting under the Physician Payment Sunshine Act**

The FDA's proposed Physician Payment Sunshine Act is due to come into force later this year. This will be important in the future as it affects sponsors giving any money to doctors working on clinical trials. Under the Act, data must be collected from August 1st 2013, with reports being sent to the CMS by March 31st 2014.





When in force, the following details will need to be reported:		
	Applicable manufacturer or GPO's name	
	Covered Recipient's	
	Amount of payment or other transfer of value	
	Date of payment or other transfer of value	
	Form of payment or other transfer of value	
	Nature of payment	
	The name of the related drug, device, biological or supply	
	National Drug Code (NDC) of related covered drug/biological, if any	
	Eligibility for delayed publication (research payments)	
	Name of entity that received the payment or other transfer of value, if not provided to the covered recipient directly (indirect payments)	
	Payments or transfers of value to physician owners or investors	
	Statement providing additional context for the payment or other transfer of value (optional)	

## **Whitehall Training**

The Physician Payment Sunshine Act is just one of the existing and future pieces of legislation in the new US GCP course from Whitehall Training. The course was researched and adapted by Dr Laura Brown, Director of the MSc in Clinical Research at Cardiff University, UK, and a trainer with over 11 years or experience of delivering technical, management and soft skills courses for the pharmaceutical industry.

Contact us for more infomation: Tel. 0207 009 7432 | Email: enquiries@infonetica.net